David Zaccardelli: Yes. Well, I think that — and you saw it in the trial ensifentrine has been used and can be used as monotherapy as well as we studied in combination with LAMA and LABA. I think it works in all these settings and even in addition to ICS. So we’re very comfortable with ensifentrine’s use along the complete treatment paradigm in COPD. And that’s why I mentioned in my remarks that because of its effect both in efficacy and safety and overall benefit to risk, we think ensifentrine is going to change exactly how COPD is treated, where you’re going to see ensifentrine utilized earlier in the treatment paradigm. And we think avoiding ICS is always a positive attribute, especially in those patients who don’t require ICS.
And in addition, those that are on triple therapy, who have really limited to no other choices, ensifentrine, again with its benefit to risk can play a role in helping those patients. And so we see it used a little everywhere, again in the treatment paradigm.
Boobalan Pachaiyappan: One final question from me, so given your substantial cash balance and recent success of ensifentrine program, can you talk about the strategic vision for the company over the next three to five years?
David Zaccardelli: Yes, sure. Very good question. Clearly, as we’ve been focused over the past two, three years, execution on ensifentrine for COPD has been critical and will continue to be so. So in the short term, of course, we have an NDA in the medium term. We’re looking for approval and launch in the COPD space. As I mentioned, that’s going to be groundbreaking in the field of COPD, and we look forward to helping millions of patients with ensifentrine in that space, specifically in the U.S., but also throughout the world and I think that’s an incredible opportunity over the coming years. In addition to that, we have mentioned previously, we are moving forward and in the early stages of a combination product development of a LAMA plus ensifentrine, which we think makes incredible amount of sense.
We know the field is set up for combination therapy as well, and we look forward to updating everybody on the progress of that. In addition, of course, ensifentrine has a lot of opportunity in other respiratory diseases, asthma, for example, cystic fibrosis, possibly ITF and so there are a lot of opportunities for us to explore. We are looking to our partnership strategy with regard to these other indications because they will probably include other delivery devices, MDI or DPI. We think leveraging our partner’s experience or own proprietary devices makes a lot of sense and so we look forward to expanding into these under indications via a partnership primarily while we continue to create the value for Verona Pharma through ensifentrine and COPD in the nebulized route, and as I mentioned, through the combination product development.
Boobalan Pachaiyappan: All right. Congrats and thanks for taking my questions.
David Zaccardelli: Thanks so much.
Operator: Our next question will come from Yasmeen Rahimi with Piper Sandler. You may now go ahead.
Unidentified Analyst: Hi guys. This is Lauren on for Yas. Just a few questions. The first, based on physician feedback at the moment, which patients would they want to put on ensifentrine? And then second, have payers commented at all about the potential ensifentrine to reduce overall COPD healthcare utilization or is the focus more narrow and short-term? Thanks.
David Zaccardelli: Chris, do you want to take down on those two?
